Showing 1387 results
-
Press release /Novartis COVID-19 Response Fund will provide grants of up to USD 1 million to support communities around the world most impacted by the Coronavirus outbreak Novartis to join collaborative R…
-
Press release /Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division addresses urgent unmet needs of low- and lower-middle-income countries to treat patients with COVID-19…
-
Press release /Basel, August 6, 2019 – Today the FDA released a statement addressing data integrity issues with the Biologics License Application (BLA) for Zolgensma® (onasemnogene abeparvovec-xioi). First and…
-
Press release /Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1] Cardiology experts…
-
Press release /STRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus…
-
Press release /Decision brings hope of longer and better life with fewer hospitalizations for millions of Europeans with symptomatic chronic heart failure with reduced ejection fraction Entresto is the…
-
Press release /Basel, June 25, 2025 – Novartis today announced that its previously announced tender offer (the “Offer”) by Redwood Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of…
-
Press release /Results from a one-year study of efficacy and safety of Aimovig in chronic migraine and data from a three-year analysis assessing safety and tolerability of Aimovig in episodic migraine will be…
-
Press release /Latest data confirm an estimated 45% of patients who received Tafinlar® + Mekinist® combination therapy are alive versus 31% of patients on BRAF monotherapy[1] Second trial to confirm three-year…